

|   |  |
|---|--|
| <b>Johnson &amp; Johnson</b><br>Innovative Medicine | <b>Data Sharing Request Due Diligence Assessment</b> |
|---|--|

| General Information   |   |
|---|---|
| YODA Project (Protocol) ID:   | 2025-0132   |
| Date Proposal Received by YODA Project:   | 18-Feb-2025   |
| Product Name(s):  | Bapineuzumab  |
| Condition(s) Studied:   | Alzheimer Disease   |
| NCT Number(s), Protocol Number(s) and Title(s):   | NCT00574132 - <b>ELN115727-301</b><br>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non-Carriers |
| Proposal Review   |   |
| Question 1:<br>The clinical trial data from the study/studies listed above were previously identified and approved as being available for a data sharing request. <b>Is there any reason why the study/studies listed should no longer be shared?</b> | No  |
| Comments if 'Yes':  |   |
| Question 2:<br>On review of the proposal, is there any data that has been requested that may be <b>missing</b> from the clinical database?  | No  |
| Comments if 'Yes':  |   |
| Question 3:<br>Is a similar analysis underway, or completed and pending disclosure by J&J?  | No  |
| Comments if 'Yes':  |   |